

Amoebic Meningoencephalitis: Etiology, Infection and Prevention

Jafar Ahmed, Nazeer Hyder, Christopher Meusburger, Nicole Rosteski, Nicole Sottile,
& Tyler Welch

Faculty: Subhajit Dasgupta PhD and Hareesh Gugnani PhD

Medical Case Study

A 15 year old male is brought in by his mother to the clinic and presents with severe headache, nausea, a stiff neck, signs of delirium and vomiting. He has a body temperature of 39.3°C (102.7°F), pulse rate of 96, respiratory rate of 24 breaths per minute and a blood pressure of 140/92mm Hg. His mother informs you that her son was perfectly fine a week ago. About three days prior however, their entire family had spent the hot summer day at the lake. To confirm your suspicions you order a CSF test that indicates the presence of *Naegleria fowleri* organism., you begin treatment by administering Miltefosine and Voriconazole with ice bags packed around the patient.


CSF serum Results:

Test	Result	Normal
Red Blood Cells	25000/mm ³	4.52-5.90 x10 ³ /mm ³
White Blood Cells	22000/mm ³	4500-1000/mm ³
Glucose	10mg/100 mL	140mg/mL



MRI

The patient's MRI was obtained and diffuse encephalitis can be seen




Primary Amoebic Meningoencephalitis

Naegleria fowleri

Free living microscopic ameba

Primary cause of Amoebic
meningoencephalitis

Most commonly found in fresh and
warm water of lakes, rivers and
springs




Amoebic Meningoencephalitis

Acanthamoeba Species

- Microscopic free living ameba responsible for:
 - Acanthamoeba keratitis
 - Granulomatous Encephalitis
 - Disseminated infection
- Found in bodies of fresh water

Balamuthia mandrillasis

- Free living ameba found in soil, spread through contact of open wounds



Pathogenesis

Etiological agent of PAM - Naegleria fowleri

Free-living organisms with no human carrier states

Rapid onset of infection and ultimately death

Penetration of olfactory mucosa

Mucinolytic protein Nfa1 degradation and cytolysis

Cribriform plate invasion permitting subarachnoid space entry

CSF nutrients and high cerebral O₂ content facilitates growth

Choroid plexus entry through Foramen of Luschka & Magendie

Trophozoites exhibit promitotic multiplication and form lesions

BRAIN-EATING AMOEBA

Naegleria fowleri is a microscopic amoeba that lives in warm, fresh waters. It can enter the nose and pass through the sinus membranes into the olfactory bulb, reproduces by fission and spreads throughout the brain. The amoeba consumes brain tissue, causes swelling of the brain and finally death.

There are three stages in the amoeba's life cycle: cyst, trophozoite and a flagellated form. The trophozoite is the infectious form.



Pathogenesis

Etiological agents of GAE -

Acanthamoeba species and *Balamuthia mandrillaris*

Subacute presentation

Highly associated with immunocompromised patients


Inflammatory necrosis of brain tissue via amoebic infiltration

CNS access:

MC hematogenously via the respiratory tract or broken skin

1° inoculation sites and focal granulomas in the lungs & skin

Olfactory entry via *acanthamoeba* keratoconjunctivitis



Transmission PAM

- Contaminated water with *Naegleria fowleri* via nose
 - Most commonly swimming or rinsing sinuses with neti pot
 - NOT FROM DRINKING, NOT FROM PERSON-PERSON CONTACT
- Transmission path: Nose → optic nerve → brain




Transmission of GAE

- Acanthamoeba* can enter via the eye with poor contact lens hygiene, or wearing contacts during swimming or hot tub use → cause infection of the cornea
- Also through the skin via cut/wound → blood → other parts of body
- Balamuthia mandrillaris* → respiratory tract or through cut or ulcerated skin

Not transmitted from patient to patient

HIV/Immunocompromised/transplant patients



Signs and Symptoms of PAM

- Start within 1 to 9 days
- 2 Stages
- Death within 1- 18 days after symptoms begin
- Stage 1 (early infection)
 - Severe frontal headache, fever, nausea, vomiting, taste and smell change
- Stage 2 (late infection)
 - Stiff neck, seizures, altered mental status, hallucinations, coma


Signs and Symptoms of GAE

- Mental status change
- loss of coordination fever, muscular weakness, double vision, photophobia, or other neurological problems



Treatment

Miltefosine - anti-leishmania




Successfully treats *Balamuthia* and disseminated *Acanthamoeba* infections.

Mix with Voriconazole and hypothermia for best results

Four survivors, one is arbitrary (PAM)

Prior treatment: amphotericin B, at maximally tolerated doses, with adjunctive rifampin and doxycycline and ceftriaxone.



Prevention

Knowledge and information

Avoidance of potentially infested waters

When potential exists utilize nose plugs

In swimming pools, ensure adequate chlorination



Epidemiology: Endemic Regions

Global



PAM and GAE reports from US, Australia and Europe

Reporting Bias

Balamuthia South America


United States

PAM more common in warmer regions and warmer months



Over half of reports in Florida and Texas

Epidemiology: Infection by Month




Epidemiology: Demographics

Can infect all age groups but
83% in children

Most common in first 3
decades

Male to Female ratio of
PAM is 2:1

Male to Female ratio of GAE
is 5:1



Conclusion

PAE is a result of infection by *N. fowleri's* invasion of the cranium through the cribriform plate, where it quickly overwhelms tissue and causes lesions in the brain. Similarly also caused by amoebas *Acanthamoeba* and *B. mandrillaris* in immunocompromised patients, is Granulomatous Amoebic encephalitis.

Both pathologies present with typical signs of CNS pathology including altered mental status and neurological dysfunction

Both diseases have similar epidemiologies, treatment, and prevention.

There are extremely rarely reported cases, most presenting in young children, and endemic to regions with warm bodies of water

Treatment includes administration of anti-leishmaniasis like miltefosine




References

Schuster FL, Guglielmo BJ, Visvesvara GS. In-vitro activity of miltefosine and voriconazole on clinical isolates of free-living amebas: *Balamuthia mandrillaris*, *Acanthamoeba* spp., and *Naegleria fowleri*. *External Web Site Icon J Eukaryot Microbiol.* 2006;53:121-6.

Linam WM, Ahmed M, Cope JR, Chu C, Visvesvara GS, da Silva AJ, Qvarnstrom Y, Green J. Successful treatment of an adolescent with *Naegleria fowleri* primary amebic meningoencephalitis. *External Web Site Icon Pediatrics.* 2015;135:e744.

Goswick SM, Brenner GM. Activities of azithromycin and amphotericin B against *Naegleria fowleri* in vitro and in a mouse model of primary amebic meningoencephalitis. *Antimicrob Agents Chemother.* 2003 Feb. 47(2):524-8.

Dorlo T, Balasegaram M, Beijnen J, Vries P. Miltefosine: A review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. Research Gate. https://www.researchgate.net/figure/230570941_fig2_figure-3-antileishmanial-mechanism-of-action-of-miltefosine-the-various-proposed. Published July 2012. Accessed July 26, 2016.



References Continued

Centers for Disease Control and Prevention

<http://www.cdc.gov/parasites/acanthamoeba/amebic-encephalitis.html>

Instabeat

<http://www.instabeat.me/blog/2013/01/03/pros-and-cons-of-wearing-a-nose-clip-while-swimming/>

Naegleria fowleri — Primary Amebic Meningoencephalitis (PAM) — Amebic Encephalitis. CDC.

<http://www.cdc.gov/parasites/naegleria/infection-sources.html>. Published April 22, 2016. Accessed July 26, 2016.

Tolan RW. Amebic Meningoencephalitis. MedScape. <http://emedicine.medscape.com/article/996227-overview#a7>. Published November 17, 2015. Accessed July 26, 2016.

Mayer P, Larkin J, Hennessy J. Amebic encephalitis. *NCBI*. April 2011. <http://www.ncbi.nlm.nih.gov/pmc/articles/pmc3114370/>. Accessed July 26, 2016.

